AbCellera Biologics (ABCL) Tax Provisions: 2021-2023
Historic Tax Provisions for AbCellera Biologics (ABCL) over the last 3 years, with Dec 2023 value amounting to -$1.5 million.
- AbCellera Biologics' Tax Provisions rose 4.41% to -$1.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$27.6 million, marking a year-over-year decrease of 134.29%. This contributed to the annual value of -$37.5 million for FY2024, which is 35.85% down from last year.
- Latest data reveals that AbCellera Biologics reported Tax Provisions of -$1.5 million as of Q4 2023, which was up 86.39% from -$10.7 million recorded in Q3 2023.
- In the past 5 years, AbCellera Biologics' Tax Provisions registered a high of $62.2 million during Q1 2022, and its lowest value of -$10.7 million during Q3 2023.
- Over the past 3 years, AbCellera Biologics' median Tax Provisions value was -$776,500 (recorded in 2022), while the average stood at $9.9 million.
- In the last 5 years, AbCellera Biologics' Tax Provisions surged by 655.76% in 2022 and then slumped by 7,301.98% in 2023.
- Over the past 3 years, AbCellera Biologics' Tax Provisions (Quarterly) stood at $24.8 million in 2021, then crashed by 106.13% to -$1.5 million in 2022, then rose by 4.41% to -$1.5 million in 2023.
- Its Tax Provisions stands at -$1.5 million for Q4 2023, versus -$10.7 million for Q3 2023 and -$7.5 million for Q2 2023.